Roche Holding’s (ROG) Buy Rating Reaffirmed at JPMorgan Chase & Co.
Several other equities analysts also recently weighed in on ROG. Citigroup Inc. reiterated a buy rating on shares of Roche Holding in a research note on Thursday, June 23rd. Goldman Sachs Group Inc. reiterated a buy rating on shares of Roche Holding in a research note on Tuesday, July 19th.
Shares of Roche Holding (VTX:ROG) traded up 0.21% during trading on Monday, reaching CHK 241.50. 638,017 shares of the company traded hands. The stock has a market capitalization of CHK 205.80 billion and a PE ratio of 22.48. Roche Holding has a 12-month low of CHK 229.90 and a 12-month high of CHK 281.40. The firm’s 50-day moving average is CHK 241.43 and its 200-day moving average is CHK 246.09.
About Roche Holding
Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.